143 related articles for article (PubMed ID: 14763948)
1. Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy.
Maetzke J; Hinrichs R; Staib G; Scharffetter-Kochanek K
Allergy; 2004 Feb; 59(2):237-8. PubMed ID: 14763948
[No Abstract] [Full Text] [Related]
2. Tolerance of Fondaparinux in Immediate-type Hypersensitivity to Heparins.
Trog LM; Kahle B; Schindewolf M; Jappe U; Ludwig RJ
Am J Med; 2015 Nov; 128(11):e21-2. PubMed ID: 26169891
[No Abstract] [Full Text] [Related]
3. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids.
Gerhardt A; Zotz RB; Stockschlaeder M; Scharf RE
Thromb Haemost; 2007 Mar; 97(3):496-7. PubMed ID: 17334521
[No Abstract] [Full Text] [Related]
4. [A study of 19 cases of allergy to heparins with positive skin testing].
Phan C; Vial-Dupuy A; Autegarden JE; Amsler E; Gaouar H; Abuaf N; Pecquet C; Francès C; Soria A
Ann Dermatol Venereol; 2014 Jan; 141(1):23-9. PubMed ID: 24461090
[TBL] [Abstract][Full Text] [Related]
5. Intolerance of fondaparinux in a patient allergic to heparins.
Hirsch K; Ludwig RJ; Lindhoff-Last E; Kaufmann R; Boehncke WH
Contact Dermatitis; 2004 Jun; 50(6):383-4. PubMed ID: 15274739
[No Abstract] [Full Text] [Related]
6. Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux.
Harr T; Scherer K; Tsakiris DA; Bircher AJ
Allergy; 2006 Jun; 61(6):787-8. PubMed ID: 16677252
[No Abstract] [Full Text] [Related]
7. A rare cutaneous manifestation of hemorrhagic bullae to low-molecular-weight heparin and fondaparinux: report of two cases.
Komforti MK; Bressler ES; Selim MA; Bressler GS; Ortel TL
J Cutan Pathol; 2017 Jan; 44(1):104-106. PubMed ID: 27766660
[No Abstract] [Full Text] [Related]
8. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.
Parody R; Oliver A; Souto JC; Fontcuberta J
Haematologica; 2003 Nov; 88(11):ECR32. PubMed ID: 14607764
[TBL] [Abstract][Full Text] [Related]
9. Delayed hypersensitivity to heparin in a patient with cancer: fondaparinux may be safe but needs to be tested.
Colagiovanni A; Rizzi A; Buonomo A; De Pasquale T; Pecora V; Sabato V; Aruanno A; Pascolini L; Nucera E; Schiavino D
Contact Dermatitis; 2010 Aug; 63(2):107-8. PubMed ID: 20629676
[No Abstract] [Full Text] [Related]
10. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT).
Rota E; Bazzan M; Fantino G
Thromb Haemost; 2008 Apr; 99(4):779-81. PubMed ID: 18392338
[No Abstract] [Full Text] [Related]
11. Fondaparinux as an alternative therapy in heparin-induced delayed-type hypersensitivity skin lesions.
O'Meara AC; Demarmels Biasiutti F; Heizmann M
Thromb Haemost; 2007 Dec; 98(6):1389-91. PubMed ID: 18064346
[No Abstract] [Full Text] [Related]
12. [Fondaparinux for thrombosis prevention after orthopaedic surgery: a revolution?].
Monreal M
Med Clin (Barc); 2003 May; 120(20):775-6. PubMed ID: 12797930
[No Abstract] [Full Text] [Related]
13. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Thachil J
Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
[TBL] [Abstract][Full Text] [Related]
14. Skin reactions due to low molecular weight heparin in pregnancy: a strategic dilemma.
Verdonkschot AE; Vasmel WL; Middeldorp S; van der Schoot JT
Arch Gynecol Obstet; 2005 Feb; 271(2):163-5. PubMed ID: 15112083
[TBL] [Abstract][Full Text] [Related]
15. [Fondaparinux and lepirudin as therapeutic alternatives in a disseminated eczematous skin reaction to low-molecular-weight heparin].
Santiago Sánchez-Mateos DI; Eguren C; de Argila D; Sánchez-Pérez J
Actas Dermosifiliogr; 2010 Jul; 101(6):556-8. PubMed ID: 20738979
[No Abstract] [Full Text] [Related]
16. Delayed-type skin reaction to the heparin-alternative danaparoid.
Szolar-Platzer C; Aberer W; Kränke B
J Am Acad Dermatol; 2000 Nov; 43(5 Pt 2):920-2. PubMed ID: 11044823
[TBL] [Abstract][Full Text] [Related]
17. Fondaparinux as anticoagulant in a pregnant woman with heparin allergy.
Wijesiriwardana A; Lees DA; Lush C
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):147-9. PubMed ID: 16479197
[TBL] [Abstract][Full Text] [Related]
18. Unexpected delayed-type hypersensitivity skin reactions to the ultra-low-molecular-weight heparin fondaparinux.
Maetzke J; Hinrichs R; Schneider LA; Scharffetter-Kochanek K
Allergy; 2005 Mar; 60(3):413-5. PubMed ID: 15679737
[No Abstract] [Full Text] [Related]
19. Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy.
Utikal J; Peitsch WK; Booken D; Velten F; Dempfle CE; Goerdt S; Bayerl C
Thromb Haemost; 2005 Oct; 94(4):895-6. PubMed ID: 16270653
[No Abstract] [Full Text] [Related]
20. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
